The introduction of the fusion inhibitors in the HAART-regimens

New Microbiologica

Volumn 27, Issue 2 SUPPL. 1, 2004, Pages 11-16

  Hasson, H ^a   Castagna, A ^a   Clementi, M ^a   Menzo, S ^a,b   Danise, A ^c   Lazzarin, A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Laboratory of Virology ^*

Author keywords

Enfuvirtide; Fusion inhibitors; HAART; HIV resistance

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; GLYCOPROTEIN GP 41;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENES, ENV; HIV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDE FRAGMENTS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 11844275297     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. CASTAGNA A., BISWAS P., BERETTA A., LAZZARIN A. (2004). From discovery of biological mechanisms to drug development: the appealing story of entry/fusion inhibitors. (Drug, submitted).
2. CHEN R.Y., KILBY J.M., SAAG M.S. (2002). Enfuvirtide. Expert Opin Investig Drugs, 11, 1837-1843.
3. DE CLERCQ E. (2001). New developments in anti-HIV chemotherapy. Curr. Med. Chem., 8, 1543-1572.
4. DEEKS S.G. (2000). Determinants of virological response to antiretroviral therapy; implications for long-term strategies. Clin Infect Dis, 30, Suppl 2; S177-S184.
5. KILBY J.M., HOPKINS S., VENETTA T.M., DIMASSIMO B., CLOUD G.A., LEE J.Y., ALLDREDGE L., HUNTER E., LAMBERT D., BOLOGNESI D., MATTHEWS T., JOHNSON M.R., NOWAK M.A., SHAW G.M., SAAG M.S. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med, 4, 11, 1302-1307.
6. KILBY J.M., LALEZARI J.P., ERON J.J., CARLSON M., COHEN C., ARDUINO R.C., GOODGAME J.C., GALLANT J.E., VOLBERDING P., MURPHY R.L., VALENTINE F., SAAG M.S., NELSON E.L., SISTA P.R., DUSEK A. (2002). The safety, plasma phermacokinetics and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adolts. AIDS Res Hum Retroviruses, 18: 10, 685-693.
7. LALEZARI JP, HENRY K, O'HEARN M, MONTANER JS, PILIERO PJ, TROTTIER B, WALMSLEY S, COHEN C, KURITZES DR, ERON JJ JR, CHUNG J, DEMASI R, DONATACCI L, DROBNES C, DELEHANTY J AND SALGO M (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med, 348, 22, 2175-2185.
8. LALEZARI J.P., ERON J.J., CARLSON M., COHEN C., DEJESUS E., ARDUINO R.C., GALLANT J.E., VOLBERDING P., MURPHY R.L., VALENTINE E, NELSON E.L., SISTA P.R., DUSEK A., KILBY J.M. (2004). A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitors-naive HIV-infected adults. Antiviral Ther (in press).
9. LALEZARI J.P., ERON J.J., CARLSON M. (2003). A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS, 17; 619-618.
10. LAZZARIN A, CLOTET B, COOPER D, REYNES J, ARASTEH K, NELSON M, KATLAMA C, STELLBRINK HJ, DELFRAISSY JF, LANGE J, HUSON L, DEMASI R, WAT C, DELEHANTY J, DROBNES C AND SALGO M (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med, 348, 22, 2186-2195.
11. MASIHI K.N. (2003). Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases. Expert Opin Ther Patents, 13, (6): 867-882.
12. MENZO S., CASTAGNA A., MONACHETTI A., HASSON H., DANISE A., CARINI E., BAGNARELLI P., LAZZARIN A. AND CLEMENTI M. (2004). Geno-phenotype to enfuvirtide of HIV mutants selected in vivo and their relative fitness. Antimicrob Agents Chemother; 27, 51-62.
13. RACE E., DAM E., OBRY V., PAULOUS S., CLAVEL F. (1999) Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS, 13, 2061-2068.
14. ROUSSEAU M.N., VERGNE L., MONTES B., PEETERS M., REYNES J., DELAPORTE E., SEGONDY M. (2001). Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1 infected patients with failure of higly active antiretroviral therapy. J Acquir Immune Defic Syndr, 26: 395.
15. rd Intrescience Conf on Antimicr Ag and Chemother (ICAAC), Chicago Sept 14-17.
16. WIE X., DECKER J.M., LIU H. (2002). Emergence of resistant human immunodeficiency virus type I in patients receiving fusion inhibitor T-20) monotherapy. Antimicrob Agents Chemother, 46, 1896-1905.
17. WILD C., GREENWELL T., MATTHEWS T. (1993). A synthetic pepetide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses, 9, 1051-1053.
18. WALMSLEY S., HENRY K., KATLAMA C., NELSON M., CASTAGNA A., REYNES J., CLOTET B., HUI J., SALGO M., DEMASI R., DELEHANTY J. (2003). Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis. 15; 188 (12):1827-33.